Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259581 · ClinicalTrials.gov registry record · Phase 1
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03259581: Completed Phase 1 study, sponsored by University of Minnesota.
NCT03259581 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03259581, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
Primary Outcome
Percentage of adverse events following TACE
Interventions
- COMBINATION_PRODUCT Transarterial chemoembolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2022-02-01 |
| Phase | Phase 1 |
What the finished NCT03259581 record still lists
NCT03259581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Transarterial chemoembolization is the first listed.
NCT03259581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03259581 about?
NCT03259581 is a clinical study titled "Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin". The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
What is the current status of trial NCT03259581?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-01-02. Estimated completion is 2022-02-01.
What interventions are being tested in trial NCT03259581?
The interventions under investigation include: Transarterial chemoembolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03259581?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03259581's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI